Nucle.ai
Nucleai is a company focused on AI-Driven Spatial Biomarkers for next-generation therapeutics. They leverage geospatial AI methods to analyze and interpret cellular interactions in patient biopsies, translating them into actionable insights for life-saving treatments and diagnostics. Their technology is the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program. Nucleai's platform analyzes various image modalities (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics) to optimize biomarker scoring, determine biomarker prevalence and mechanism of action, and predict therapy response. They aim to transform patient care by bringing together experts in pathology, medicine, biology, engineering, and artificial intelligence to revolutionize precision medicine.
Nucle.ai
Nucleai is a company focused on AI-Driven Spatial Biomarkers for next-generation therapeutics. They leverage geospatial AI methods to analyze and interpret cellular interactions in patient biopsies, translating them into actionable insights for life-saving treatments and diagnostics. Their technology is the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program. Nucleai's platform analyzes various image modalities (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics) to optimize biomarker scoring, determine biomarker prevalence and mechanism of action, and predict therapy response. They aim to transform patient care by bringing together experts in pathology, medicine, biology, engineering, and artificial intelligence to revolutionize precision medicine.